New Opportunities of Topic Therapy of Foot Mycosis
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: to evaluate the efficacy and safety of combined external use of naftifine hydrochloride 1% and salicylic ointment 3% in the treatment of foot mycosis.
Materials and methods. Under observation were 12 patients with mycosis of the feet, incl. 7 (58%) women and 5 (42%) men, aged 37 to 69 years. The disease duration ranged from 1 to 13 years. Naftifine hydrochloride 1% and salicylic ointment 3% were prescribed to all patients for 2 weeks once a day. Evaluation of clinical efficacy was performed on days 3, 7, and 14 of the treatment. To assess the mycological recovery, bacterioscopic examination was performed on the 14th day of therapy, as well as on the 7th and 10th day after its termination.
Results. Analysis of the regression of the clinical manifestations of the disease showed a high efficacy of the proposed treatment regimen. Already on day 3 of therapy, a marked decrease in itching, erythema, edema, desquamation and hyperkeratosis was observed in all patients. At the time of termination of therapy (14 days), all patients showed clinical recovery, manifested by a complete regression of rash, inflammatory manifestations in the lesions, the absence of hyperkeratosis and complete epithelialization of cracks. Bacterioscopic examination on the 14th day of therapy, as well as on the 7th and 10th day after its termination, negative results were obtained in 100% of patients, which indicated mycological recovery.
Conclusions. The proposed combined method of external use of naftifine hydrochloride 1% and salicylic ointment 3% in the treatment of mycosis of the feet is effective and safe, demonstrates a pronounced therapeutic effect, is well tolerated by patients.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Иванова М.А., Огрызко Е.В., Бендриковская А.И. Динамика заболеваемости дерматомикозами в РФ в 2003–2007 гг. // Клиническая дерматология и венерология. – 2009. – № 2. – С. 26–31.
Кузнецов Д.А., Кулешова Л.Ю., Попугаева В.А., Волкова Д.А. Маркетинговые исследования группы лекарственных средств салициловой кислоты // Материалы межрегиональной научной конференции с международным участием рязанского государственного медицинского университета имени академика И.П. Павлова /Под общей редакцией В.А. Кирюшина. – 2014. – С. 322–323.
Матушевская Е.В., Свирщевская Е.В. Нафтифин в терапии грибковых инфекций кожи: 40 лет успеха. Вестн. дерматол венерол 2014; (2): 72–77.
Сергеев А.Ю., Сергеев В.Ю. Грибковые инфекции. Руководство для врачей. – М.: Бином, 2008. – 450 с.
Сергеев В.Ю., Сергеев А.Ю. Дерматофитии: новое в диагностике, терапии и профилактике наиболее распространенных микозов человека. Consilium medicum. – Дерматология. – 2008; 1: 30-5.
Сергеев Ю.В., Бунин В.М., Сергеев А.Ю. Поликлинические микозы // Кремлевская медицина. – 2010. – № 5. – С. 24–29.
Соколова Т.В., Малярчук А.П. Клинико-эпидемиологический мониторинг поверхностных микозов в России и совершенствование терапии // Русский медицинский журнал. – 2011. – Т. 19, № 21. – С. 1327–1332
Экзодерил: новые подходы к терапии микозов и инфекционно-воспалительных дерматозов. Пособие для врачей. Под ред. Сергеева Ю.В. – М.: Национальная академия микологии: 2004. – 24 с.
Ghannoum M., Isham N., Verma A., Plaum S., Fleischer A. Jr, Hardas B. In vitro antifungal activity of naftifine hydrochloride against dermatophytes. Antimicrob Agents Chemother 2013 Sep; 57(9):4369–72.
Maraki S. Epidemiology of dermatophytoses in Crete, Greece between 2004 and 2010. G Ital Dermatol Venereol. 2012 Jun; 147(3): 315–9.
Monk J.P., Brogden R.N. Naftifine. A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs 1991; 42:659-72.
Nenoff P, Kruger C, Ginter‐Hanselmayer G, Tietz HJ. Mycology – an update. Part 1: Dermatomycoses: causative agents, epidemiology and pathogenesis. J Dtsch Dermatol Ges. 2014; 12(3): 188-210.
Petranyi G., Ryder N.S., Stutz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984; 224 (4654): 1239–241.
Plaum S., Verma A., Fleischer A.B. Jr. et al. Detection and relevance of naftifine hydrochloride in the stratum corneum up to four weeks following the last application of naftifine cream and gel, 2%. J Drugs Dermatol. 2013; 12(9): 1004–8.
Rotta I, Ziegelmann PK, Otuki MF. et al. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison metaanalysis involving 14 treatments. JAMA Dermatol. 2013 Mar;149(3):341349
Smith E.B., Breneman D.L. Griffith R.F. et al. Double-blind comparison of naftifine cream and clotrimazole/betametasone dipropionate cream in the treatment of tinea pedis. J Am Acad Dermatol 1992; 26; 125–27.
